Contact Information: For More Information Contact: Dawn Van Zant 800-665-0411 Ann-Marie Fleming 866-725-2554 Web Site: www.InvestorIdeas.com
Global Search for a Cancer Cure Drives Market for Benda Pharmaceutical's Gene Therapy Medicine
China-AsiaStocks.com Profiles New Showcase China Stock for Investors Following Sector; Benda Pharmaceutical, Inc., Producer of Conventional and Traditional Chinese Medicines
POINT ROBERTS, WA and DELTA, BC--(Marketwire - October 9, 2007) - InvestorIdeas.com and
China-AsiaStocks.com, its investor and industry portal focused on the
China-Asia sector, announce
China-based pharmaceutical company,
Benda Pharmaceutical, Inc. (OTCBB : BPMA ), as a new showcase company.
Benda is involved in the production of both conventional and
Traditional Chinese Medicines and most notably is responsible for the
production of Gendicine®, the world's first commercialized gene therapy
medicine for the treatment of cancer.
China, a nation that is facing escalating cancer rates, heart disease and
an aging population, is currently exploring options for significantly
reforming its health system in an effort to provide improved access to
affordable health treatment and services. The Country's healthcare
challenges have been driving growth in its pharmaceutical and biotech
market, leading many to believe that China has the potential to become the
world's fifth largest drug market by 2010.
Benda Pharmaceutical owns and operates five plants combining to produce
more than thirty medicines and medicine ingredients, including the addition
of the gene therapy cancer medicine, Gendicine®, acquired through its
purchase of SiBiono Genetech Corp., the developers of this promising
treatment.
According to the Company, Gendicine® supplemented by radiotherapy,
chemotherapy or heat treatment, raises treatment efficacy to 3x that of all
other tumor treatment methods. In clinical trials for 135 patients affected
by head and neck tumors, 64% had their tumors eliminated after one month of
Gendicine® treatment, marking a 340% increase in efficacy relative to
traditional treatments.
Benda Pharmaceutical is working to build their presence within the fast
growing Chinese market and forecasts that Gendicine® will generate $20.8
million in revenue in 2008 up from estimates of $12 million for 2007. In
total, the Company anticipates revenues to reach $40.7 million in 2007 and
progressing upwards to $76.2 million in 2008.
For Additional Information Visit: http://www.investorideas.com/co/bpma/.
Benda Pharmaceutical Inc. is a Showcase Company on InvestorIdeas.com.
Compensation is disclosed in disclaimer below.
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research
resource portal specialized in sector investing covering over thirty
industry sectors and global markets including China, India, Middle East and
Australia. China-AsiaStocks.com is an investor portal within
InvestorIdeas.com covering news and market info, as well as a growing
directory of stocks in the sector.
InvestorIdeas.com Disclaimer: www.InvestorIdeas.com/About/Disclaimer.asp. Our sites do not make recommendations, but
offer information portals to research news, articles, stock lists and
recent research. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. We attempt to research
thoroughly, but we offer no guarantees as to the accuracy of information
presented. All Information relating to featured companies is sourced from
public documents and/ or the company and is not the opinion of our web
sites. This site is currently compensated by featured companies, news
submissions and online advertising. Benda Pharmaceutical, Inc. (OTCBB : BPMA ) $4000USD per month.